Breaking News Instant updates and real-time market news.

MRK

Merck

$83.30

0.52 (0.63%)

06:46
06/18/19
06/18
06:46
06/18/19
06:46

Merck: FDA approves KEYTRUDA as monotherapy for SCLC

Merck announced that the U.S. FDA has approved KEYTRUDA, Merck's anti-PD-1 therapy, as monotherapy for the treatment of patients with metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. This accelerated approval is based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. This marks the first indication for KEYTRUDA in SCLC.

  • 20

    Jun

  • 20

    Jun

  • 24

    Jun

  • 16

    Jul

  • 30

    Jul

  • 06

    Aug

  • 16

    Sep

  • 20

    Sep

MRK Merck
$83.30

0.52 (0.63%)

05/21/19
MSCO
05/21/19
NO CHANGE
Target $84
MSCO
Overweight
Morgan Stanley not lowering Keytruda projections despite Merck disappointment
After Merck announced that Keytruda monotherapy failed to beat chemotherapy in a Phase 3 triple negative breast cancer, or TNBC, trial, Morgan Stanley analyst David Risinger said he is not r lowering his Keytruda projections as he is hopeful that the drug can succeed in KN-355, another TNBC trial, later this year. In that trial, a combination of Keytruda plus chemo will be investigated in first-line TNBC, noted Risinger, who has an Overweight rating and $84 price target on Merck shares.
05/22/19
GUGG
05/22/19
NO CHANGE
GUGG
Buy
Guggenheim says Peloton Therapeutics a good strategic fit for Merck
Guggenheim analyst Seamus Fernandez said he thinks Peloton Therapeutics is a good strategic fit for Merck citing the "rational targeting" of a resistance mechanism to VEGF-TKIs commonly used in the treatment of Renal Cell Carcinoma, or RCC. Fernandez, who sees the transaction being minimally dilutive and having no impact on 2019 adjusted EPS guidance, keeps a Buy rating on Merck shares.
05/28/19
GSCO
05/28/19
INITIATION
Target $85
GSCO
Neutral
Merck initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Terence Flynn started Merck with a Neutral rating and $85 price target. The analyst projects the company's earnings and revenue growth through 2022 will be in-line with consensus. As such, he views the stock as fairly valued.
05/30/19
GUGG
05/30/19
NO CHANGE
GUGG
Buy
Array BioPharma could be seen as target after 'de-risking' data, says Guggenheim
Guggenheim analyst Michael Schmidt said Array Biopharma (ARRY) may be perceived by investors as a theoretical acquisition target following the disclosure of Phase 3 interim results of Braftovi/Mektovi in BRAF+ colorectal cancer, which he views as positive and a "de-risking event." 67% of announced acquisitions in oncology with a comparable market cap to Array had what he would consider major pipeline de-risking events in the 6 months prior to their deal announcements, Schmidt tells investors. Merck (MRK) and Pfizer (PFE) "seem to have most bandwidth for a deal," said Schmidt, who added that those two along with Bristol-Myers (BMY), AstraZeneca (AZN) and Roche (RHHBY) scored highest as possible large cap theoretical acquirers of Array in his analysis. Schmidt raised his price target on Array Biopharma shares to $38 from $37, though his analysis suggests a potential $40-$50 acquisition price if the company were to be bought.

TODAY'S FREE FLY STORIES

LVMUY

LVMH

$0.00

(0.00%)

13:52
07/15/19
07/15
13:52
07/15/19
13:52
Hot Stocks
LVMH announces partnership with Stella McCartney »

Stella McCartney and LVMH…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

SCHW

Charles Schwab

$40.49

0.47 (1.17%)

13:51
07/15/19
07/15
13:51
07/15/19
13:51
Recommendations
Charles Schwab analyst commentary  »

Wells says Schwab deal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 27

    Oct

AMC

AMC Entertainment

$9.45

(0.00%)

13:45
07/15/19
07/15
13:45
07/15/19
13:45
Options
AMC Entertainment call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

SPY

SPDR S&P 500 ETF Trust

$300.31

-0.37 (-0.12%)

, SPX

S&P 500

$0.00

(0.00%)

13:43
07/15/19
07/15
13:43
07/15/19
13:43
Periodicals
Trump ponders firing Commerce Secretary Wilbur Ross, NBC News says »

According to an earlier…

SPY

SPDR S&P 500 ETF Trust

$300.31

-0.37 (-0.12%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDCO

The Medicines Co.

$36.65

-0.03 (-0.08%)

13:35
07/15/19
07/15
13:35
07/15/19
13:35
Options
Medicines Company put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTGN

Neon Therapeutics

$4.61

0.3 (6.96%)

13:30
07/15/19
07/15
13:30
07/15/19
13:30
Recommendations
Neon Therapeutics analyst commentary  »

Neon Therapeutics'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

SYMC

Symantec

$21.73

-3.83 (-14.98%)

, AVGO

Broadcom

$289.18

3.79 (1.33%)

13:27
07/15/19
07/15
13:27
07/15/19
13:27
Periodicals
Broadcom was willing to pay up $28.25 per share for Symantec, Reuters reports »

Symantec (SYMC) walked…

SYMC

Symantec

$21.73

-3.83 (-14.98%)

AVGO

Broadcom

$289.18

3.79 (1.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CARA

Cara Therapeutics

$25.55

1.25 (5.14%)

13:25
07/15/19
07/15
13:25
07/15/19
13:25
Options
Cara Therapeutics call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:25
07/15/19
07/15
13:25
07/15/19
13:25
Conference/Events
Stephens consumer/poultry & egg analysts hold analyst/industry conference call »

Analysts provide an…

A

Agilent

$69.90

-1.75 (-2.44%)

13:25
07/15/19
07/15
13:25
07/15/19
13:25
Conference/Events
The Brookings Institution to hold a conference »

8th annual Municipal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jul

GOOG

Alphabet

$1,146.02

1.47 (0.13%)

, GOOGL

Alphabet Class A

$1,146.04

0.74 (0.06%)

13:24
07/15/19
07/15
13:24
07/15/19
13:24
Periodicals
Trump administration 'taking aim' at Google, FBN's Gasparino says »

Charles Gasparino of Fox…

GOOG

Alphabet

$1,146.02

1.47 (0.13%)

GOOGL

Alphabet Class A

$1,146.04

0.74 (0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 25

    Jul

  • 08

    Aug

  • 27

    Oct

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
07/15/19
07/15
13:17
07/15/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
07/15/19
07/15
13:16
07/15/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLF

Herbalife Nutrition

$41.12

-0.47 (-1.13%)

13:15
07/15/19
07/15
13:15
07/15/19
13:15
Options
Herbalife put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

OSAGY

Osram

$0.00

(0.00%)

13:09
07/15/19
07/15
13:09
07/15/19
13:09
Hot Stocks
Osram announces interest from AMS, sees 'rather low' probability of deal »

Osram Licht said it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAESY

BAE Systems

$0.00

(0.00%)

13:09
07/15/19
07/15
13:09
07/15/19
13:09
Hot Stocks
BAE Systems reports award of $45M contract from U.S. Army »

The U.S. Army has awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBGI

Sinclair Broadcast

$58.58

-0.46 (-0.78%)

, GIII

G-III Apparel

$28.05

-0.36 (-1.27%)

13:07
07/15/19
07/15
13:07
07/15/19
13:07
On The Fly
Fly Insider: G-III, Target among week's notable insider transactions »

Welcome to "Fly Insider,"…

SBGI

Sinclair Broadcast

$58.58

-0.46 (-0.78%)

GIII

G-III Apparel

$28.05

-0.36 (-1.27%)

OPK

Opko Health

$2.14

-0.025 (-1.15%)

THO

Thor Industries

$58.96

-0.4 (-0.67%)

GEF

Greif

$33.90

-0.68 (-1.97%)

INSG

Inseego

$5.19

0.03 (0.58%)

FDS

FactSet

$293.90

-2.66 (-0.90%)

TREE

LendingTree

$428.63

-4.28 (-0.99%)

MKC

McCormick

$159.84

1.31 (0.83%)

TGT

Target

$86.80

-0.73 (-0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 12

    Aug

  • 21

    Aug

  • 05

    Sep

  • 19

    Sep

  • 19

    Sep

  • 25

    Sep

  • 13

    Nov

YELP

Yelp

$35.68

-0.37 (-1.03%)

13:05
07/15/19
07/15
13:05
07/15/19
13:05
Options
Yelp call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CONN

Conn's

$18.07

-0.21 (-1.15%)

13:03
07/15/19
07/15
13:03
07/15/19
13:03
Hot Stocks
Conn's settles with SEC over underwriting policies, bad debt provisions »

Conn's announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

ET

Energy Transfer LP

$14.82

(0.00%)

13:02
07/15/19
07/15
13:02
07/15/19
13:02
Hot Stocks
Energy Transfer LP announce binding supplemental open season for Bakken »

Energy Transfer LP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BX

Blackstone

$45.86

-0.17 (-0.37%)

13:02
07/15/19
07/15
13:02
07/15/19
13:02
Hot Stocks
Blackstone agrees to acquire Vungle, terms not disclosed »

Blackstone announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

BIDU

Baidu

$115.31

0.41 (0.36%)

, SNAP

Snap

$15.59

-0.01 (-0.06%)

13:02
07/15/19
07/15
13:02
07/15/19
13:02
Hot Stocks
Baidu, Snap renew sales partnership »

Baidu (BIDU) and Snap…

BIDU

Baidu

$115.31

0.41 (0.36%)

SNAP

Snap

$15.59

-0.01 (-0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 23

    Jul

INTC

Intel

$49.91

(0.00%)

, AMD

AMD

$34.42

1.22 (3.67%)

12:56
07/15/19
07/15
12:56
07/15/19
12:56
Recommendations
Intel, AMD analyst commentary at RBC Capital »

RBC sees AMD continuing…

INTC

Intel

$49.91

(0.00%)

AMD

AMD

$34.42

1.22 (3.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

FB

Facebook

$203.64

-1.265 (-0.62%)

12:52
07/15/19
07/15
12:52
07/15/19
12:52
Hot Stocks
Facebook's Marcus says company won't immediately profit from Libra »

In testimony for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 17

    Jul

  • 24

    Jul

CYTK

Cytokinetics

$11.04

0.02 (0.18%)

, AMGN

Amgen

$177.08

2.21 (1.26%)

12:51
07/15/19
07/15
12:51
07/15/19
12:51
Recommendations
Cytokinetics, Amgen analyst commentary at Piper Jaffray »

Piper reiterates…

CYTK

Cytokinetics

$11.04

0.02 (0.18%)

AMGN

Amgen

$177.08

2.21 (1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 09

    Sep

  • 16

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.